A Dark Vector Cognition product

Item 2. Properties

2K characters. Original on sec.gov · Markdown

Item 2. Properties

Our executive offices are located in Madison, New Jersey; in 2016, we announced that we plan to relocate our executive offices and corporate support functions to Secaucus, New Jersey in 2017. We maintain clinical testing laboratories throughout the continental United States; in several instances a joint venture of which we are a partner maintains the laboratory. We also maintain offices, data centers, call centers, distribution centers and patient service centers at locations throughout the United States. In addition, we maintain offices, patient service centers and clinical laboratories in locations outside the United States, including in Puerto Rico, Mexico, India and Ireland. Our properties that are not owned are leased on terms and for durations that are reflective of commercial standards in the communities where these properties are located. We believe that, in general, our facilities are suitable and adequate for our current and anticipated future levels of operation and are adequately maintained. We believe that if we were unable to renew a lease on any of our facilities, we could find alternative space at competitive market rates and relocate our operations to such new location without material disruption to our business. Several of our principal facilities are highlighted below.

LocationLeased or Owned
Sacramento, California (laboratory)Leased
West Hills, California (laboratory)Leased
San Juan Capistrano, California (laboratory)Owned
Tampa, Florida (laboratory)Owned
Atlanta, Georgia (laboratory)Owned
Chicago, Illinois (2) (laboratories)One owned, one leased
Marlborough, Massachusetts (laboratories)Leased
Baltimore, Maryland (laboratory)Owned
Teterboro, New Jersey (laboratory)Owned
Philadelphia, Pennsylvania (laboratory)Leased
Dallas, Texas (laboratory)Leased
Chantilly, Virginia (laboratory)Leased
Lenexa, Kansas (laboratory)Owned
Greensboro, North Carolina (laboratory)Leased

Previous: Item 1B. Unresolved Staff Comments · Next: Item 3. Legal Proceedings